• $5.1M
    Market Cap
  • -99.87%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 55
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

What's Going On With CDT Equity Shares On Monday?

CDT Equity (NASDAQ:CDT) shares rose 14.71% to $4.68 on Monday despite the health care sector declining 2.63% over the past 30 days. The rally comes after the biopharmaceutical company disclosed a widened net loss of $39.1 million for 2025 and filed a non-timely 10K. Technical analysis shows the stock trading 49.1% below its 20-day moving average and 84.6% below its 100-day moving average, with the stock down 99.83% over the past 12 months. The company is set to report earnings on April 24.

04/13/2026, 12:38 PM • Benzinga

CDT Positions for Transformational Growth

CDT Equity Inc. (NASDAQ:CDT) announced multiple strategic initiatives to enhance shareholder value, including its 20% equity stake acquisition in Sarborg AI for $115 million, continued development of its pharmaceutical portfolio with AstraZeneca-licensed assets, and evaluation of capital markets initiatives to strengthen financial flexibility.

03/04/2026, 8:30 AM • Benzinga

Peers

Statistics

More
Day Range
$0.81
$0.90
$0.85
1-Year Range
$0.39
$9.35
$0.85
Latest Close$0.85
Change
-$0.05 (-5.60%)
Volume473,333
Market Cap$5.1M
Shares Outstanding4.9M
P/E (TTM)0.002
Diluted EPS (TTM)$512.66
Enterprise Value$9.2M

Information as of 06/02/2026

Company Profile

$5.1M
Market Cap
-$34.8M
Net Income
Sector: Healthcare
Industry: Biotechnology
4581 Tamiami Trail North, Naples, FL, United States, 34103
646 491 9132

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Key Executives

  • Andrew Regan
  • James Bligh
  • Joanne Holland

Current Ownership Distribution

  • Insiders32.3M (66.97%)
  • Institutions9.2M (19.06%)
  • Mutual Funds6.7M (13.97%)
  • Other0 (0.00%)